Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

M. Alejandra Tortorici(Centre National de la Recherche Scientifique), Martina Beltramello(Vir Biotechnology (Switzerland)), Florian A. Lempp(VIR Biotechnology (United States)), Dora Pinto(Vir Biotechnology (Switzerland)), Ha V. Dang(University of Washington), Laura E. Rosen(VIR Biotechnology (United States)), Matthew McCallum(University of Washington), John E. Bowen(University of Washington), Andrea Minola(Vir Biotechnology (Switzerland)), Stefano Jaconi(Vir Biotechnology (Switzerland)), Fabrizia Zatta(Vir Biotechnology (Switzerland)), Anna De Marco(Vir Biotechnology (Switzerland)), Barbara Guarino(Vir Biotechnology (Switzerland)), Siro Bianchi(Vir Biotechnology (Switzerland)), Elvin J. Lauron(VIR Biotechnology (United States)), Heather Tucker(VIR Biotechnology (United States)), Jiayi Zhou(VIR Biotechnology (United States)), Alessia Peter(Vir Biotechnology (Switzerland)), Colin Havenar‐Daughton(VIR Biotechnology (United States)), Jason A. Wojcechowskyj(VIR Biotechnology (United States)), James Brett Case(Washington University in St. Louis), Rita E. Chen(Washington University in St. Louis), Hannah Kaiser(VIR Biotechnology (United States)), Martin Montiel-Ruiz(VIR Biotechnology (United States)), Marcel Meury(VIR Biotechnology (United States)), Nadine Czudnochowski(VIR Biotechnology (United States)), Roberto Spreafico(VIR Biotechnology (United States)), Josh R. Dillen(VIR Biotechnology (United States)), Cindy Ng(VIR Biotechnology (United States)), Nicole Sprugasci(Vir Biotechnology (Switzerland)), Katja Culap(Vir Biotechnology (Switzerland)), Fabio Benigni(Vir Biotechnology (Switzerland)), Rana Abdelnabi(Rega Institute for Medical Research), Caroline S. Foo(Rega Institute for Medical Research), Michael Schmid(Vir Biotechnology (Switzerland)), Elisabetta Cameroni(Vir Biotechnology (Switzerland)), Agostino Riva(Luigi Sacco Hospital), Arianna Gabrieli(Luigi Sacco Hospital), Massimo Galli(Luigi Sacco Hospital), Matteo Samuele Pizzuto(Vir Biotechnology (Switzerland)), Johan Neyts(Rega Institute for Medical Research), Michael Diamond(Washington University in St. Louis), Herbert W. Virgin(Washington University in St. Louis), Gyorgy Snell(VIR Biotechnology (United States)), Davide Corti(Vir Biotechnology (Switzerland)), Katja Fink(Vir Biotechnology (Switzerland)), David Veesler(University of Washington)
Science
September 24, 2020
Cited by 625Open Access
Full Text

Abstract

Efficient therapeutic options are needed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 September 2020. We report the isolation and characterization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-CoV-2 challenge. Cryo-electron microscopy structures show that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 also locks the spike in a closed conformation by recognition of a quaternary epitope spanning two adjacent receptor-binding domains. Antibody cocktails that include S2M11, S2E12, or the previously identified S309 antibody broadly neutralize a panel of circulating SARS-CoV-2 isolates and activate effector functions. Our results pave the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the emergence of viral escape mutants.


Related Papers

No related papers found

Powered by citation graph analysis